THE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS
|
|
- Louisa Harris
- 5 years ago
- Views:
Transcription
1 THE IASLC/ERS/ATS ADENOCARCINOMA CLASSIFICATION RATIONALE AND STRENGTHS PULMONARY PATHOLOGY SOCIETY USCAP, BALTIMORE, March 2, 2013 William D. Travis, M.D. Dept of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY Worldwide, lung cancer is the most common cause of major cancer mortality in men and the second most common in women. Recent therapeutic advances have led to a revolution in the lung cancer field in discovering therapeutically tractable oncogene dependency, that have major implications for patient evaluation and approach to diagnosis. The 2011 IASLC/ATS/ERS Classification of Lung Adenocarcinoma addresses these issues. 1 This classification was developed based on an evidence-based approach by an international multidisciplinary panel including pathologists, oncologists/respiratory physicians, radiologists, molecular biologists, and thoracic surgeons. 1 Multiple paradigm shifts are outlined that have a major impact on clinical practice for pathologists as well as the entire multidisciplinary team caring for lung cancer patients. Two review articles one on small biopsies/cytology specimens and the other on resection specimens addressed primarily to pathologists are about to be published and are currently available online. 2, 3 Since 70% of lung cancer patients present in advanced stages, their diagnosis is usually established based on small biopsies and/or cytology specimens and the primary therapy is chemotherapy; the remaining patients are usually resectable and surgery is the primary treatment. In order to address all types of cancer patients, there are two major components to the classification based on the type of specimen: 1) small biopsies and cytology or 2) resection. Because previous WHO classifications did not provide specific criteria and terminology for pathologic diagnosis of lung cancer in small biopsies and cytology, 4 this new classification is more clinically relevant as it addresses these small specimens and addresses molecular testing. In recent years, three therapeutic advances for advanced NSCLC have made accurate histologic diagnosis a critical step in developing a personalized approach to management. The first, relates to tyrosine kinase inhibitors as first line therapy in patients with advanced lung adenocarcinoma with EGFR mutations. 5 For this reason, in the new classification EGFR mutation testing is recommended for advanced lung cancer patients with a histologic diagnosis of adenocarcinoma. Second, patients with adenocarcinoma or NSCLC, not otherwise specified (NSCLC-NOS) are more responsive to pemetrexed than those squamous cell carcinoma. 6 Third, squamous cell carcinoma is associated with life threatening hemorrhage in patients treated with bevacizumab therefore it is contraindicated in lung cancer patients with this histology. 7 Fourth, crizotinib is an FDA-approved therapy for advanced adenocarcinomas with ALK rearrangements Both EGFR mutations and ALK rearrangements are almost exclusively seen in lung adenocarcinomas. So a pathologic diagnosis of adenocarcinoma or squamous cell carcinoma will determine patient eligibility for EGFR mutation testing and for specific therapies. In all of these clinical trials the pathologic diagnoses were based on light microscopy with or without mucin stains but not on the basis of immunohistochemical stains. 5-7 While much progress has been made in identifying validated molecular targets for lung adenocarcinoma, only recently have potential targets been identified for squamous cell carcinoma
2 including FGFR1 amplification and DDR2 mutations which may render these patients sensitive to FGFR 11, inhibition and dasatinib respectively. The Cancer Genome Atlas (TCGA) project sponsored by the National Cancer Institute has identified molecular alterations that may represent molecular targets in the majority of lung squamous cell carcinomas. 13 In the future this may lead to effective targeted therapies for lung squamous cell carcinomas, which would only increase the importance of accurate pathologic classification in small biopsies and cytology. CLASSIFICATION BASED ON SMALL BIOPSIES AND CYTOLOGY Now that lung cancer therapy is personalized for individual patients based on the histologic type of lung cancer and molecular status, the pathologist s role and approach to lung cancer diagnosis in small biopsies and cytology have been affected dramatically. The need to classify non-small cell carcinoma (NSCLC) further to distinguish squamous cell carcinoma from adenocarcinoma has not existed until recently so the frequency of NSCLCnot otherwise specified (NOS) has been increasing up to 20-40%. Now pathologists need to make an effort to make a more specific diagnosis using special stains. Tumors that show morphologic squamous or adenocarcinoma differentiation can be classified as squamous cell carcinoma or adenocarcinoma, respectively. However, for those tumors that lack clear differentiation by morphology and would be classified as NSCLC-NOS in the past, now need to be evaluated by immunohistochemistry. The recommendation is to use a single adenocarcinoma marker such as TTF-1 and a single squamous marker such as the recently described p40 antibody. 14 If a NSCLC-NOS by light microscopy shows a staining pattern that clearly points to adenocarcinoma (TTF-1 positive, p40 negative), the tumor can be classified as NSCLC, favor adenocarcinoma. If such a tumor stains with a squamous pattern (p40 positive, TTF-1 negative), then it can be called NSCLC, favor squamous cell carcinoma. If the tumor does not show clear differentiation by immunohistochemistry, it should remain as NSCLC-NOS. These terms and criteria will help track the former NOS tumors that are being reclassified with the addition of special stains for future clinical trials. Advanced stage tumors classified as adenocarcinoma, NSCLC, favor adenocarcinoma or NSCLC-NOS should be tested for EGFR mutation; mutation positive patients are eligible for tyrosine kinase inhibitor therapy. If there is no EGFR mutation, recent data suggests these patients are candidates for EML4-ALK fusion testing and if positive they can receive the FDA approved drug crizotinib, 10 and if negative these patients are eligible for pemetrexed or bevacizumab based chemotherapeutic regimens. In the new classification, a limited use of special stains is recommended for NSCLC- NOS by light microscopy in order to try to classify these tumors further. Minimizing special stains is helpful to maximize the amount of tissue available for molecular testing. 1 A new responsibility for pathologists, in addition to making a correct diagnosis, is to manage these small biopsies and cytology specimens strategically so there is sufficient tissue preserved for molecular studies. A new emphasis is made on the need for a multidisciplinary approach to lung cancer diagnosis. One of the central proposals in this classification is that each institution needs to have a multidisciplinary strategy that addresses how to obtain these small specimens, how to process them in the pathology laboratory, how to preserve material for molecular testing, sending specimens to the molecular laboratory for expedited testing and the reporting the results in a pathology report. It may be useful to have a multidisciplinary committee to develop this strategy and to monitor issues in an ongoing fashion. 2
3 CLASSIFICATION BASED ON RESECTION SPECIMENS Major changes are also recommended for adenocarcinomas diagnosed in resection specimens: 1 1) the term bronchioloalveolar carcinoma (BAC) should not be used anymore, because tumors previously classified under as BAC are represented by five different tumors in this classification; 2), for solitary tumors measuring 3cm, new concepts of adenocarcinoma in situ (AIS) and minimally invasive adenocarcinoma (MIA) have been introduced for lesions that have no invasion or 5mm invasion, respectively; these patients should have 100% or near 100% disease free survival (DFS); 3) for invasive adenocarcinomas, comprehensive histologic subtyping is recommended for evaluation with classification according to the predominant subtype; 4) micropapillary adenocarcinoma is proposed as a new subtype with a poor prognosis; 5) the term lepidic replaces BAC for tumors with a predominant component formerly called nonmucinous BAC, and the term lepidic predominant adenocarcinoma is recommended along with discontinuing the term mixed subtype ; 6) invasive mucinous adenocarcinoma (IMA) is the term used to replace those formerly classified as mucinous BAC. IMA are strongly correlated with KRAS mutation Recently strong survival correlations were demonstrated using this classification in Stage I adenocarcinomas with the following 5-year DFS: AIS and MIA (100%), lepidic (90%), acinar (84%), papillary (83%), and there was a poor prognostic group: micropapillary (67%), solid (70%), colloid (71%) predominant tumors as well as invasive mucinous adenocarcinoma (75%). 15 Comprehensive histologic subtyping is performed by making semiquantitative estimation of each of the patterns in 5% increments. A deliberate choice needs to be made to give one pattern the largest percentage. It is useful to record in diagnostic reports each adenocarcinoma subtype that is present with the percentages. This approach may also provide a basis for architectural grading of lung adenocarcinomas Early reproducibility studies have shown moderate to substantial inter-observer agreement among pathologists for the predominant pattern. A reproducibility study of classical and difficult selected images of the major lung adenocarcinoma subtypes circulated among a panel of 26 expert lung cancer pathologists documented kappa values of / and /- 0.14, respectively. 18 A recent study of reproducibility for predominant pattern showed moderate to good κ-values of 0.44 to 0.72 for pulmonary pathologists. For untrained pathologists κ-values were expectedly lower ranging from 0.38 to 0.47, but these improved after a training session to 0.51 to 0.66 and reevaluation by the same reviewers led to very high κ-values between Reproducibility improves after training sessions. However, work is needed to improve separation of difficult problems such as lepidic versus acinar or papillary and micropapillary versus papillary patterns. 18, Since this classification was initially published, there are a growing number of studies of resected lung adenocarcinomas that have demonstrated its utility in identifying significant prognostic subsets and molecular correlations according to the predominant 15, 16, patterns. In summary this classification outlines many paradigm shifts in lung cancer diagnosis that crystalize the importance of histology and genetics in personalized medicine for lung cancer patients. Evidence-based recommendations are made that will transform the clinical practice of all physicians involved with lung cancer diagnosis. Reference List 1. Travis WD, Brambilla E, Noguchi M et al. The New IASLC/ATS/ERS international multidisciplinary lung adenocarcinoma classification. J Thoracic Oncol 2011;6(2):
4 2. Travis WD, Brambilla E, Noguchi M et al. Lung Cancer Diagnosis in Small Biopsies and Cytology: Implications of the 2011 IASLC/ATS/ERS. Arch Pathol Lab Med 2013;e pub ahead. 3. Travis WD, Brambilla E, Noguchi M et al. Diagnosis of Lung Adenocarcinoma in Resected Specimens: Implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Classification. Arch Pathol Lab Med 2013;e pub ahead. 4. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC; Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10): Scagliotti GV, Parikh P, von PJ et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26(21): Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11): Sasaki T, Janne PA. New Strategies for Treatment of ALK Rearranged Non-Small Cell Lung Cancers. Clin Cancer Res 2011;17(23): Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011;17(8): Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18): Dutt A, Ramos AH, Hammerman PS et al. Inhibitor-Sensitive FGFR1 Amplification in Human Non- Small Cell Lung Cancer. PLoS ONE 2011;6(6):e Weiss J, Sos ML, Seidel D et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2(62):62ra Hammerman PS, Hayes DN, Wilkerson MD et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417): Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol 2012;25(3): Yoshizawa A, Motoi N, Riely GJ et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 2011;24(5):
5 16. Sica G, Yoshizawa A, Sima CS et al. A grading system of lung adenocarcinomas based on histologic pattern is predictive of disease recurrence in stage I tumors. Am J Surg Pathol 2010;34(8): Kadota K, Suzuki K, Kachala SS et al. A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. Mod Pathol 2012;25(8): Thunnissen FB, Beasley MB, Borczuk A et al. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. Mod Pathol 2012;25(12): Warth A, Stenzinger A, von Brunneck AC et al. Interobserver variability in the application of the novel IASLC/ATS/ERS classification. Eur Respir J 2012;40(5): Warth A, Stenzinger A, von Brunneck AC et al. Interobserver variability in the application of the novel IASLC/ATS/ERS classification. Eur Respir J 2012;40(5): Warth A, Cortis J, Fink L et al. Training increases concordance in classifying pulmonary adenocarcinomas according to the novel IASLC/ATS/ERS classification. Virchows Arch 2012;461(6): Warth A, Muley T, Meister M et al. The novel histologic IASLC/ATS/ERS classification system of invasive pulmonary adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 2012;30(13): Russell PA, Wainer Z, Wright GM, Daniels M, Conron M, Williams RA. Does lung adenocarcinoma subtype predict patient survival?: A clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 2011;6(9): Yoshizawa A, Sumiyoshi S, Sonobe M et al. Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations: Analysis of 440 Japanese Patients. J Thorac Oncol 2013;8(1): Shim HS, Lee dh, Park EJ, Kim SH. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the international association for the study of lung cancer/american thoracic society/european respiratory society lung adenocarcinoma classification. Arch Pathol Lab Med 2011;135(10): Sterlacci W, Savic S, Schmid T et al. Tissue-Sparing Application of the Newly Proposed IASLC/ATS/ERS Classification of Adenocarcinoma of the Lung Shows Practical Diagnostic and Prognostic Impact. Am J Clin Pathol 2012;137(6):
UPDATES IN THE SURGICAL PATHOLOGY OF LUNG CANCER. Four Ps of Pulmonary Cytopathology: Procedural, Predictive, Personalized and Participatory
UPDATES IN THE SURGICAL PATHOLOGY OF LUNG CANCER travisw@mskcc.org Four Ps of Pulmonary Cytopathology: Procedural, Predictive, Personalized and Participatory American Society of Cytopathology Companion
More informationHOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
More informationThe 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach
The 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach Dr. Carol Farver Director, Pulmonary Pathology Pathology and Laboratory Medicine Institute Objectives Discuss
More informationExtensive immunohistochemistry was performed on this case, in the referring community /district hospital. This showed the following results:
Case 1 The New Classification Helped Keith Kerr Clinical history This 75 year old female patient presented with an increasing cough and some vague symptoms of pain over the left lower chest wall. She is
More informationPrudence Anne Russell 1,2, Gavin Michael Wright 3,4
Editorial Page 1 of 7 Predominant histologic subtype in lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients: discovery of a holy grail? Prudence Anne Russell
More informationThe new international multidisciplinary lung adenocarcinoma
Eur Respir J 2011; 38: 239 243 DOI: 10.1183/09031936.00026711 CopyrightßERS 2011 EDITORIAL Paradigm shifts in lung cancer as defined in the new IASLC/ATS/ERS lung adenocarcinoma classification W.D. Travis*,"",
More informationDisclosure of Relevant Financial Relationships NON-SMALL CELL LUNG CANCER: 70% PRESENT IN ADVANCED STAGE
MORPHOLOGY AND MOLECULAR TESTING IN NON-SMALL CELL OF LUNG NEW FRONTIEIRS IN CYTOPATHOLOGY PRACTICE American Society for Cytopathology San Antonio, Texas Sunday March 5, 2017 Disclosure of Relevant Financial
More informationLung cancer is now a major cause of death in developed
Original Article New IASLC/ATS/ERS Classification and Invasive Tumor Size are Predictive of Disease Recurrence in Stage I Lung Adenocarcinoma Naoki Yanagawa, MD, PhD,* Satoshi Shiono, MD, PhD, Masami Abiko,
More informationQuality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE:
More informationCytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics. Mercè Jordà, University of Miami
Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics Mercè Jordà, University of Miami Mortality Lung cancer is the most frequent cause of cancer incidence and mortality
More informationQuality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination
Quality ID #395: Lung Cancer Reporting (Biopsy/Cytology Specimens) National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE:
More informationNon-Small Cell Lung Carcinoma - Myers
Role of Routine Histology and Special Testing in Managing Patients with Non- Small Cell Lung Carcinoma Jeffrey L. Myers, M.D. A. James French Professor Director, Anatomic Pathology & MLabs University of
More informationSurgical pathology of early stage non-small cell lung carcinoma
Review Article Page 1 of 8 Surgical pathology of early stage non-small cell lung carcinoma Mary Beth Beasley 1, Francine R. Dembitzer 1, Raja M. Flores 2 1 Department of Pathology, 2 Department of Thoracic
More informationLung cancer is the leading cause of cancer-related
Original Articles Correlation of Mutation Status With Predominant Histologic Subtype of Adenocarcinoma According to the New Lung Adenocarcinoma Classification of the International Association for the Study
More informationGround Glass Opacities
Ground Glass Opacities A pathologist s perspective Marie-Christine Aubry, M.D. Professor of Pathology Mayo Clinic Objectives Discuss the proposed new pathologic classification of adenocarcinoma with historical
More informationMinor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph Node Metastasis and Poor Prognosis
Ann Surg Oncol (2016) 23:2099 2105 DOI 10.1245/s10434-015-5043-9 ORIGINAL ARTICLE THORACIC ONCOLOGY Minor Components of Micropapillary and Solid Subtypes in Lung Adenocarcinoma are Predictors of Lymph
More informationInterobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas
Eur Respir J 212; 4: 1221 1227 DOI:.1183/931936.219211 CopyrightßERS 212 Interobserver variability in the application of the novel IASLC/ATS/ERS classification for pulmonary adenocarcinomas Arne Warth*,
More informationSteering Committee. Waiting on photo. Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD.
Steering Committee Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD MD, PhD Waiting on photo Paul Van Schil, MD, PhD William D. Travis, MD Ming-Sound Tsao,
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationThe lung adenocarcinoma guidelines: what to be considered by surgeons
Review Article The lung adenocarcinoma guidelines: what to be considered by surgeons Rodrigo A. S. Sardenberg 1, Evandro Sobroza Mello 1, Riad N. Younes 2 1 Hospital Alemão Oswaldo Cruz, São Paulo, Brazil;
More informationSecond predominant subtype predicts outcomes of intermediatemalignant invasive lung adenocarcinoma
European Journal of Cardio-Thoracic Surgery 51 (2017) 218 222 doi:10.1093/ejcts/ezw318 Advance Access publication 6 October 2016 ORIGINAL ARTICLE Cite this article as: Ito M, Miyata Y, Yoshiya T, Tsutani
More informationLung Neoplasia II Resection specimens Pathobasic. Lukas Bubendorf Pathology
Lung Neoplasia II Resection specimens Pathobasic Lukas Bubendorf Pathology Agenda Preneoplastic lesions Histological subtypes of lung cancer Histological patterns of AC Cells of origin and characteristic
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationA Multi-Resolution Deep Learning Framework for Lung Adenocarcinoma Growth Pattern Classification
MIUA2018, 053, v4 (final): Multi-Resolution CNN for Lung Growth Pattern Classification 1 A Multi-Resolution Deep Learning Framework for Lung Adenocarcinoma Growth Pattern Classification Najah Alsubaie
More informationHistology: Its Influence on Therapeutic Decision Making
Histology: Its Influence on Therapeutic Decision Making Mark A. Socinski, MD Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology Co-Director, UPMC
More informationInternational association for the study of lung cancer/american thoracic society/european respiratory
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. William Travis, Elisabeth
More informationResearch Article Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically Resected Lung Adenocarcinoma
BioMed Research International, Article ID 64568, 6 pages http://dx.doi.org/.55/24/64568 Research Article Prognostic Implication of Predominant Histologic Subtypes of Lymph Node Metastases in Surgically
More informationRecent advances in the management of non small-cell
Original Article Mitosis Trumps T Stage and Proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification for Prognostic Value in
More informationThe histological grading of lung cancer is a significant
ORIGINAL ARTICLE Interobserver Agreement in the Nuclear Grading of Primary Pulmonary Adenocarcinoma Yoshimasa Nakazato, MD,* Akiko Miyagi Maeshima, MD, Yuichi Ishikawa, MD, Yasushi Yatabe, MD, Junya Fukuoka,
More informationMOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE
25 th IAP-Arab Division Conference 07-09 November 2013, Amman, Jordan MOLECULAR PREDICTIVE MARKERS OF LUNG CARCINOMA: KFSH&RC EXPERIENCE Fouad Al Dayel, MD, FRCPA, FRCPath Professor and Chairman Department
More informationMolecular Diagnosis of Lung Cancer
Molecular Diagnosis of Lung Cancer Lucian R. Chirieac, M.D. Assistant Professor of Pathology Harvard Medical School Staff Pathologist, Department of Pathology Brigham and Women's Hospital 75 Francis Street
More informationSteering Committee. Waiting on photo. Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD.
Steering Committee Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD MD, PhD Waiting on photo Paul Van Schil, MD, PhD William D. Travis, MD Ming-Sound Tsao,
More informationUpdate on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.
1 Our speaker for this program is Dr. Anja Roden, an associate professor of Laboratory Medicine and Pathology at Mayo Clinic as well as consultant in the Anatomic Pathology Laboratory and co-director of
More informationFrequencies of actionable mutations and survival in variants of invasive adenocarcinoma of lung
Original Article Frequencies of actionable mutations and survival in variants of invasive adenocarcinoma of lung Zhengbo Song 1,2 *, Tangfeng Lv 1 *, Yiping Zhang 2, Yong Song 1 1 Department of Respiratory
More informationClassification of non-small cell lung carcinomas (NSCLC)
Classification of non-small cell lung carcinomas (NSCLC) 1. NordiQC Conference on Standardization in Applied Immunohistochemistry 4-7 June 2013 Birgit Guldhammer Skov, MD. DMeSci, Dept. Of Pathology, Rigshospitalet,
More information8/22/2016. Major risk factors for the development of lung cancer are: Outline
Carcinomas of the Lung: Changes in Staging, Adenocarcinoma Classification and Genetics Grace Y. Lin, M.D., Ph.D. Outline Background Staging of Lung Cancer: Review of the 2010 7 th Edition of the AJCC Cancer
More informationThoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis
19 th Congress of APSR PG of Lung Cancer (ESAP): Update of Lung Cancer Thoracic CT pattern in lung cancer: correlation of CT and pathologic diagnosis Kazuma Kishi, M.D. Department of Respiratory Medicine,
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Lung Cancer T STAGE OUTLINE SURVIVAL ACCORDING TO SIZE ONLY
Pathologic Staging Updates in Lung Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
More informationIntroduction: Overview of Current Status of Lung Cancer Predictive Biomarkers
Introduction: Overview of Current Status of Lung Cancer Predictive Biomarkers Program 7:15 7:40 Translocations as predictive biomarkers in lung cancer: Overview Mari Mino Kenudson, MD 7:40 8:05 Translocation
More informationPersonalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationOriginal Articles. Current Evidence Does Not Warrant Frozen Section Evaluation for the Presence of Tumor Spread Through Alveolar Spaces
Original Articles Current Evidence Does Not Warrant Frozen Section Evaluation for the Presence of Tumor Spread Through Alveolar Spaces Ann E. Walts, MD; Alberto M. Marchevsky, MD Context. Tumor spread
More informationUtility of small biopsies for diagnosis of lung nodules: doing more with less
& 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 S43 Utility of small biopsies for diagnosis of lung nodules: doing more with less Sanjay Mukhopadhyay Department of Pathology, State University
More informationPrognostic factors in curatively resected pathological stage I lung adenocarcinoma
Original Article Prognostic factors in curatively resected pathological stage I lung adenocarcinoma Yikun Yang 1, Yousheng Mao 1, Lin Yang 2, Jie He 1, Shugeng Gao 1, Juwei Mu 1, Qi Xue 1, Dali Wang 1,
More informationReproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study
1574 & 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study Erik Thunnissen
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationLung adenocarcinoma is the most common histologic
ORIGINAL ARTICLE Validation of the IASLC/ATS/ERS Lung Adenocarcinoma Classification for Prognosis and Association with EGFR and KRAS Gene Mutations Analysis of 440 Japanese Patients Akihiko Yoshizawa,
More informationRole of molecular studies in the diagnosis of lung adenocarcinoma
& 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 S11 Role of molecular studies in the diagnosis of lung adenocarcinoma Samuel A Yousem Department of Pathology, University of Pittsburgh Medical
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationProposal of a prognostically relevant grading scheme for pulmonary squamous cell carcinoma
ORIGINAL ARTICLE LUNG CANCER Proposal of a prognostically relevant grading scheme for pulmonary squamous cell carcinoma Wilko Weichert 1,2,3, Claudia Kossakowski 1, Alexander Harms 1, Peter Schirmacher
More informationImpact of immunostaining of pulmonary and mediastinal cytology
Impact of immunostaining of pulmonary and mediastinal cytology Harman Sekhon MD, PhD Director of Cytopathology Head of Ottawa-site Ontario Tumour Bank June 20, 2014 Disclaimer Pfizer: Honorarium-Advisory
More informationEffect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study
Original Article Effect of invasive mucinous adenocarcinoma on lung cancer-specific survival after surgical resection: a population-based study Seok Whan Moon 1, Si Young Choi 2, Mi Hyoung Moon 1 1 Department
More informationSOLITARY PULMONARY NODULES
SOLITARY PULMONARY NODULES Histological subtypes of solitary pulmonary nodules of adenocarcinoma and their clinical relevance Hui-Di Hu 1*, Ming-Yue Wan 1*, Chun-Hua Xu 2,3, Ping Zhan 2,3, Jue Zou 1, Qian-Qian
More informationThe revised lung adenocarcinoma classification an imaging guide
Review Article The revised lung adenocarcinoma classification an imaging guide Natasha Gardiner 1, Sanjay Jogai 2, Adam Wallis 3 1 Specialty Registrar in Clinical Radiology, Wessex Deanery, UK; 2 Consultant
More informationShould minimally invasive lung adenocarcinoma be transferred from stage IA1 to stage 0 in future updates of the TNM staging system?
Original Article Should minimally invasive lung adenocarcinoma be transferred from stage to stage 0 in future updates of the TNM staging system? Tianxiang Chen 1,2#, Jizhuang Luo 3#, Haiyong Gu 3, Yu Gu
More informationNon Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
More informationPulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification
Review Article Pulmonary adenocarcinoma: implications of the recent advances in molecular biology, treatment and the IASLC/ATS/ERS classification Swaroop Revannasiddaiah 1, Priyanka Thakur 2, Bhaskar Bhardwaj
More informationOriginal Article Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification of lung adenocarcinoma
Int J Clin Exp Pathol 2014;7(11):8039-8045 www.ijcep.com /ISSN:1936-2625/IJCEP0002211 Original Article Correlation of EGFR mutation and histological subtype according to the IASLC/ATS/ERS classification
More informationEarly lung cancer with lepidic pattern: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma
REVIEW C URRENT OPINION Early lung cancer with lepidic pattern: adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant adenocarcinoma Wilko Weichert and Arne Warth Purpose of
More informationSteering Committee. Waiting on photo. Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD.
Steering Committee Paul A. Bunn, Jr., MD Kavita Garg, MD Kim Geisinger, MD Fred R. Hirsch, Gregory Riely, MD, PhD MD, PhD Waiting on photo Paul Van Schil, MD, PhD William D. Travis, MD Ming-Sound Tsao,
More informationBiopsy and Mutation Detection Strategies in Non-Small Cell Lung Cancer
REVIEW http://dx.doi.org/10.4046/trd.2013.75.5.181 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2013;75:181-187 Biopsy and Mutation Detection Strategies in Non-Small Cell Lung Cancer Chi
More informationLung cancer continues to be the leading cause of cancer
original article Why Do Pathological Stage IA Lung Adenocarcinomas Vary from Prognosis? A Clinicopathologic Study of 176 Patients with Pathological Stage IA Lung Adenocarcinoma Based on the IASLC/ATS/ERS
More informationApplying Genomics to Cancer 21 st September The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience
Applying Genomics to Cancer 21 st September 2015 The Frequency of EGFR mutations in Lung Adenocarcinoma: The Cardiff Experience Aled Daniels R Butler, R Attanoos, H Davies University Hospital of Wales
More informationInsulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens
Insulinoma-associated protein (INSM1) is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens Kartik Viswanathan, M.D., Ph.D New York Presbyterian - Weill
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationDetection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
Cancer and Clinical Oncology; Vol. 7, No. 1; 2018 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell
More informationClinicopathologic Characteristics of EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC) in Central New York
North American Journal of Medicine and Science Jan 2018 Vol 11 No.1 1 Original Research Clinicopathologic Characteristics of EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC) in Central New York Daniel
More informationEGFR Mutational Status of Primary Lung Adenocarcinoma in an Indian Cohort Based on 2015 WHO Classification of Lung tumors
Original Article DOI: 10.21276/APALM.1372 EGFR Mutational Status of Primary Lung Adenocarcinoma in an Indian Cohort Based on 2015 WHO Classification of Lung tumors Priyanka Yogendra Ravi 1 *, Anila Korula
More informationMutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma
Cancer Medicine ORIGINAL RESEARCH Open Access Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma Zhengbo Song 1,2, Xinmin Yu 1 & Yiping Zhang 1,2 1 Department
More informationAdditional clinical features of this patient include:
*Not an actual patient. Challenge your knowledge of biomarker testing in advanced NSCLC. Consider this case study of disease progression following chemotherapy, with insightful commentary from Dr Edward
More informationMinimally invasive adenocarcinoma. 5mm or less = microinvasion No necrosis No lymphatic or pleural invasion No spread through air-spaces (STAS)
Minimally invasive adenocarcinoma 5mm or less = microinvasion No necrosis No lymphatic or pleural invasion No spread through air-spaces (STAS) 2b lepidic acinar 2c papillary micropapillary solid 2d cribriform
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationQuan Zhang, Na Qin, Jinghui Wang, Jialin Lv, Xinjie Yang, Xi Li, Jingying Nong, Hui Zhang, Xinyong Zhang, Yuhua Wu & Shucai Zhang
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Crizotinib versus platinum-based double-agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase-positive lung adenocarcinoma
More informationPrognostic Significance of Predominant Histologic Pattern and Nuclear Grade in Resected Adenocarcinoma of the Lung
ORIGINAL ARTICLE Prognostic Significance of Predominant Histologic Pattern and Nuclear Grade in Resected Adenocarcinoma of the Lung Potential Parameters for a Grading System Jan H. von der Thüsen, MD,
More informationPulmonary adenocarcinoma Issues, Issues and more issues. Why the headache?
Issues Pulmonary adenocarcinoma Issues, Issues and more issues. Why the headache? Classification Multiple nodules Invasive size Alain Borczuk, MD Weill Cornell Medicine Chronic headache - Classification
More informationThyroid transcription factor 1 (TTF1), a homeodomaincontaining
Original Article Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD,* Rui Wang, MD, PhD,* Yuan Li, MD, Yunjian Pan, MD,* Haichuan
More informationThe practice of subtyping of non-small cell lung carcinoma
ORIGINAL ARTICLE Subtyping of Non-small Cell Lung Carcinoma A Comparison of Small Biopsy and Cytology Specimens Carlie S. Sigel, MD,* Andre L. Moreira, MD, PhD,* William D. Travis, MD,* Maureen F. Zakowski,
More informationIASLC 2011/WHO 2015 CLASSIFICATION OF LUNG ADENOCARCINOMAS
Serban Negoita Dylan Holt Marsha Dunn IASLC 2011/WHO 2015 CLASSIFICATION OF LUNG ADENOCARCINOMAS DEMOGRAPHIC PATTERNS, TRENDS, AND IMPLICATIONS FOR CANCER SURVEILLANCE Outline Relevance of lung adenocarcinoma
More informationLung cancer is the main cause of cancer-related death worldwide.
Original Article Prognostic Factors of Survival after Recurrence in Patients with Resected Lung Adenocarcinoma Jung-Jyh Hung, MD, PhD,* Yi-Chen Yeh, MD, Wen-Juei Jeng, MD, Hong-Che Chien, MD,* Yu-Chung
More informationALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationDelivering Value Through Personalized Medicine: An Industry Perspective
Delivering Value Through Personalized Medicine: An Industry Perspective Josephine A. Sollano, Dr.PH Head, Global HEOR and Medical Communications Pfizer Oncology, NY, USA josephine.sollano@pfizer.com What
More informationFast Facts: Non-Small-Cell Lung Cancer
Fast Facts Fast Facts: Non-Small-Cell Lung Cancer Mary O Brien MD FRCP Consultant Medical Oncologist The Royal Marsden NHS Foundation Trust London, UK Benjamin Besse MD PhD Thoracic Cancer Unit, Head Department
More informationLung cancer is the most common cause of cancer death in
ORIGINAL ARTICLE Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features? Catherine
More informationLin Yang 1, Yun Ling 1, Lei Guo 1, Di Ma 2, Xuemin Xue 1, Bingning Wang 1, Junling Li 2, Jianming Ying 1. Original Article.
Original Article Detection of ALK translocation in non-small cell lung carcinoma (NSCLC) and its clinicopathological significance using the Ventana immunohistochemical staining method: a single-center
More informationEGFR, Lung Cancer and Cytology. Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan.
EGFR, Lung Cancer and Cytology Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan. It is histopathologically divided into two major sub-groups: Small
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationEvolution of Pathology
1 Traditional pathology Molecular pathology 2 Evolution of Pathology Gross Pathology Cellular Pathology Morphologic Pathology Molecular/Predictive Pathology Antonio Benivieni (1443-1502): First autopsy
More informationHistopathology of NSCLC, IHC markers and ptnm classification
ESMO Preceptorship on Non-Small Cell Lung Cancer November 15 th & 16 th 2017 Singapore Histopathology of NSCLC, IHC markers and ptnm classification Prof Keith M Kerr Department of Pathology, Aberdeen University
More informationEarly-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion
Early-stage locally advanced non-small cell lung cancer (NSCLC) Clinical Case Discussion Pieter Postmus The Clatterbridge Cancer Centre Liverpool Heart and Chest Hospital Liverpool, United Kingdom 1 2
More informationEGFR. Pathway and biomarkers. Alex Soltermann
EGFR Pathway and biomarkers Alex Soltermann EGFR = HER1 signaling pathway EGFR Cheng Mod Pathol 2012 Chromosome 7p11.2, spans 200kb, 28 exons, 464 aa, 170 kda protein 2 Signal transduction pathways controlled
More informationA nonresponding small cell lung cancer combined with adenocarcinoma
Case Report A nonresponding small cell lung cancer combined with adenocarcinoma Hongyang Lu 1,2, Shifeng Yang 3 1 Zhejiang Key Laboratory of Diagnosis & Treatment Technology on Thoracic Oncology (Lung
More informationPrognosis of recurrent non small cell lung cancer following complete resection
1300 Prognosis of recurrent non small cell lung cancer following complete resection HIDEFUMI SASAKI, AYUMI SUZUKI, TSUTOMU TATEMATSU, MASAYUKI SHITARA, YU HIKOSAKA, KATSUHIRO OKUDA, SATORU MORIYAMA, MOTOKI
More informationI appreciate the courtesy of Kusumoto at NCC for this presentation. What is Early Lung Cancers. Early Lung Cancers. Early Lung Cancers 18/10/55
I appreciate the courtesy of Kusumoto at NCC for this presentation. Dr. What is Early Lung Cancers DEATH Early period in its lifetime Curative period in its lifetime Early Lung Cancers Early Lung Cancers
More informationClinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases
Original Article Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases Yuan-Yuan Lei 1,2, Jin-Ji Yang 2, Wen-Zhao Zhong 2, Hua-Jun Chen
More informationHistologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified
ORIGINAL ARTICLE Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified C. Ho md,* K.M. Tong bsc,* K. Ramsden bsc,* D.N. Ionescu md, and J. Laskin
More information